NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stockRead More

Novo Nordisk gains as 2023 sales rise 31%

Published 01/02/2024, 01:48 am
© Reuters.
NVO
-

Novo Nordisk (NYSE:NVO) shares gained more than 4% Wednesday after the company reported its latest quarterly and full-year 2023 earnings.

The company said sales increased by 31% in Danish kroner (DKK) to DKK 232.3 billion in 2023. Meanwhile, operating profit increased by 37% to DKK 102.6 billion.

"We are very pleased with the strong performance in 2023, reflecting that more than 40 million people are now benefiting from our innovative diabetes and obesity treatments," said Lars Fruergaard Jørgensen, president and CEO of NVO. "We continue to make progress on our strategic aspirations.

Reacting to the report, analysts at Jefferies maintained an Underperform rating and DKK465 price target on the stock, stating the outlook was as expected.

"4Q focus drugs Wegovy below cons as anticipated, but Ozempic 14% & Rybelsus 14% ahead as US rebates again lower than norms," the analysts wrote. "US Wegovy starter dose supply began gradually rising in Jan but will be a focus for the call. Better gross margin offset by higher spend for 5% EBIT & 5% EPS beats."

They added that the initial 2024 outlook was broadly as expected but suggests up to "+3% potential consensus sales and EBIT upgrades to the upper-ends given the higher base."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.